Milbemycin oxime

A mature reference line with current UK authorisations and extensive post-authorisation history; the exact forms are not registered in the reviewed Georgian register.

Controlled and field studies support broad cestode and nematode efficacy, including label-specific eyeworm and heartworm roles; the evidence base is mature but target and regimen remain parasite-specific.

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

A mature reference line with current UK authorisations and extensive post-authorisation history; the exact forms are not registered in the reviewed Georgian register.

Controlled and field studies support broad cestode and nematode efficacy, including label-specific eyeworm and heartworm roles; the evidence base is mature but target and regimen remain parasite-specific.

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

A mature reference line with current UK authorisations and extensive post-authorisation history; the exact forms are not registered in the reviewed Georgian register.

Controlled and field studies support broad cestode and nematode efficacy, including label-specific eyeworm and heartworm roles; the evidence base is mature but target and regimen remain parasite-specific.

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

A mature reference line with current UK authorisations and extensive post-authorisation history; the exact forms are not registered in the reviewed Georgian register.

Controlled and field studies support broad cestode and nematode efficacy, including label-specific eyeworm and heartworm roles; the evidence base is mature but target and regimen remain parasite-specific.

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

Every exact form is registered in Georgia and has current UK authorisation with a public generic assessment dossier and exact SPCs.

Bioequivalence-style regulatory assessment and exact-brand controlled Echinococcus trials support efficacy, with the mature reference-combination evidence applicable to the same doses; independent broad field evidence is less extensive than for Milbemax.

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

Every exact form is registered in Georgia and has current UK authorisation with a public generic assessment dossier and exact SPCs.

Bioequivalence-style regulatory assessment and exact-brand controlled Echinococcus trials support efficacy, with the mature reference-combination evidence applicable to the same doses; independent broad field evidence is less extensive than for Milbemax.

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

Every exact form is registered in Georgia and has current UK authorisation with a public generic assessment dossier and exact SPCs.

Bioequivalence-style regulatory assessment and exact-brand controlled Echinococcus trials support efficacy, with the mature reference-combination evidence applicable to the same doses; independent broad field evidence is less extensive than for Milbemax.

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

Every exact form is registered in Georgia and has current UK authorisation with a public generic assessment dossier and exact SPCs.

Bioequivalence-style regulatory assessment and exact-brand controlled Echinococcus trials support efficacy, with the mature reference-combination evidence applicable to the same doses; independent broad field evidence is less extensive than for Milbemax.

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

The Georgian register snapshot lists the exact authorisations only through 15-20 October 2026, with no renewal verified as of assessment. The forms appear in the current Russian national instruction but lack an EMA/FDA/VMD-style public assessment dossier and broad international regulatory history.

A manufacturer-linked 2019 controlled field report directly studied the exact species presentations and reported complete clearance across susceptible intestinal helminths; the established milbemycin-combination literature is supportive, but independent peer-reviewed exact-brand evidence is limited.

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Small flavoured weight-band tablets and single-dose intestinal-worm treatment are practical; accurate weighing, administration with food and parasite-specific monthly prevention or repeat schedules remain necessary.

The Georgian register snapshot lists the exact authorisations only through 15-20 October 2026, with no renewal verified as of assessment. The forms appear in the current Russian national instruction but lack an EMA/FDA/VMD-style public assessment dossier and broad international regulatory history.

A manufacturer-linked 2019 controlled field report directly studied the exact species presentations and reported complete clearance across susceptible intestinal helminths; the established milbemycin-combination literature is supportive, but independent peer-reviewed exact-brand evidence is limited.

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Small flavoured weight-band tablets and single-dose intestinal-worm treatment are practical; accurate weighing, administration with food and parasite-specific monthly prevention or repeat schedules remain necessary.

The Georgian register snapshot lists the exact authorisations only through 15-20 October 2026, with no renewal verified as of assessment. The forms appear in the current Russian national instruction but lack an EMA/FDA/VMD-style public assessment dossier and broad international regulatory history.

A manufacturer-linked 2019 controlled field report directly studied the exact species presentations and reported complete clearance across susceptible intestinal helminths; the established milbemycin-combination literature is supportive, but independent peer-reviewed exact-brand evidence is limited.

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Small flavoured weight-band tablets and single-dose intestinal-worm treatment are practical; accurate weighing, administration with food and parasite-specific monthly prevention or repeat schedules remain necessary.

The Georgian register snapshot lists the exact authorisations only through 15-20 October 2026, with no renewal verified as of assessment. The forms appear in the current Russian national instruction but lack an EMA/FDA/VMD-style public assessment dossier and broad international regulatory history.

A manufacturer-linked 2019 controlled field report directly studied the exact species presentations and reported complete clearance across susceptible intestinal helminths; the established milbemycin-combination literature is supportive, but independent peer-reviewed exact-brand evidence is limited.

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

Small flavoured weight-band tablets and single-dose intestinal-worm treatment are practical; accurate weighing, administration with food and parasite-specific monthly prevention or repeat schedules remain necessary.

The Georgian register snapshot lists authorisation 002535 only through 19 October 2026, and no renewal has been verified as of assessment. The form was directly studied in 2019 but is absent from the current 2024 Russian national instruction, which now lists only four other presentations.

A manufacturer-linked 2019 controlled field report directly studied this strength and reported complete clearance in small groups, including microfilariae; however, it is not peer reviewed, sample sizes were small and the current national label no longer lists this presentation.

The established active ingredients have a generally predictable safety profile at labelled doses, but exact-brand safety evidence is mainly limited to small short-term groups. Microfilaraemic animals can react, MDR1-sensitive dogs require strict dosing, and renal, hepatic, age and weight restrictions apply.

The large-dog tablet is convenient in principle, but the discrepancy between the registered presentation, the 2019 study and the current national instruction makes the current package dosing table essential before use.